Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)
Status:
Active, not recruiting
Trial end date:
2022-01-27
Target enrollment:
Participant gender:
Summary
This study is performed to investigate the long-term safety, in particular the diabetogenic
potential and immunogenicity of rhGH therapy in short children born small for gestational age
(SGA).